Accepted Manuscript

Title: Chemotherapy-Based Stem Cell Mobilisation Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens

Author: Anthony Oyekunle, Evgenii Shumilov, Philippe Kostrewa, Andreas Burchert, Lorenz Trümper, Patrick Wuchter, Gerald Wulf, Ulrike Bacher, Nicolaus Kröger


PII: S1083-8791(17)30767-X

DOI: https://doi.org/doi:10.1016/j.bbmt.2017.10.008

Reference: YBBMT 54822

To appear in: Biology of Blood and Marrow Transplantation

Received date: 26-7-2017 Accepted date: 3-10-2017



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

TITLE

Chemotherapy-based stem cell mobilisation does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens

AUTHORS

Anthony Oyekunle, Evgenii Shumilov, Philippe Kostrewa, Andreas Burchert, Lorenz Trümper, Patrick Wuchter, Gerald Wulf, Ulrike Bacher, Nicolaus Kröger

Corresponding author:

Prof. Dr. med. Nicolaus Kröger
Department of Stem Cell Transplantation
University Medical Center Hamburg-Eppendorf
Martinistrasse52
D-20246 Hamburg

Tel.: +49-(0)40-7410-54851 Fax: +49-(0)40-7410-53795

Email: nkroeger@uke.uni-hamburg.de

HIGHLIGHTS

- Novel induction regimens (NIR) have improved remission status in myeloma patients.
- Stem cell chemo-mobilization (SCCM) is associated with significant morbidity.
- SCCM fails to improve remission status in myeloma patients in the era of the NIR.
- The value of chemotherapy in SCCM compared to GCSF alone needs further study.

ABSTRACT

Introduction: Novel induction agents markedly improved remission rates in multiple myeloma (MM) and the continued use of chemotherapy for CD34⁺ stem cell mobilisation (SCM) has been questioned. We examined the additional effect of chemotherapy in SCM regarding remission status/morbidity.

Download English Version:

https://daneshyari.com/en/article/8430283

Download Persian Version:

https://daneshyari.com/article/8430283

<u>Daneshyari.com</u>